Does restarting warfarin therapy affect the risk of recurrence or thromboembolization in patients with a recent warfarin-associated intracerebral hemorrhage?
Restarting warfarin after a warfarin-associated intracerebral hemorrhage presents a clinical dilemma balancing low recurrence risk against thromboembolic risk if withheld.
Restarting warfarin therapy in patients with a recent WAICH is associated with a low risk of recurrence, but patients are subjected to known, substantial risks of warfarin use. Withholding warfarin therapy is associated with a risk of thromboembolization.
Claassen et al. (Wed,) studied this question.